PURPOSE: Recently, the Cormio et al. nomogram has been developed to predict prostate cancer (PCa) and clinically significant PCa using benign prostatic obstruction parameters. The aim of the present study was to externally validate the nomogram in a multicentric cohort. METHODS: Between 2013 and 2019, patients scheduled for ultrasound-guided prostate biopsy were prospectively enrolled at 11 Italian institutions. Demographic, clinical and histological data were collected and analysed. Discrimination and calibration of Cormio nomogram were assessed with the receiver operator characteristics (ROC) curve and calibration plots. The clinical net benefit of the nomogram was assessed with decision curve analysis. Clinically significant PCa was defined as ISUP grade group > 1. RESULTS: After accounting for inclusion criteria, 1377 patients were analysed. 816/1377 (59%) had cancer at final pathology (574/816, 70%, clinically significant PCa). Multivariable analysis showed age, prostate volume, DRE and post-voided residual volume as independent predictors of any PCa. Discrimination of the nomogram for cancer was 0.70 on ROC analysis. Calibration of the nomogram was excellent (p = 0.94) and the nomogram presented a net benefit in the 40-80% range of probabilities. Multivariable analysis for predictors of clinically significant PCa found age, PSA, prostate volume and DRE as independent variables. Discrimination of the nomogram was 0.73. Calibration was poor (p = 0.001) and the nomogram presented a net benefit in the 25-75% range of probabilities. CONCLUSION: We confirmed that the Cormio nomogram can be used to predict the risk of PCa in patients at increased risk. Implementation of the nomogram in clinical practice will better define its role in the patient's counselling before prostate biopsy.
PURPOSE: Recently, the Cormio et al. nomogram has been developed to predict prostate cancer (PCa) and clinically significant PCa using benign prostatic obstruction parameters. The aim of the present study was to externally validate the nomogram in a multicentric cohort. METHODS: Between 2013 and 2019, patients scheduled for ultrasound-guided prostate biopsy were prospectively enrolled at 11 Italian institutions. Demographic, clinical and histological data were collected and analysed. Discrimination and calibration of Cormio nomogram were assessed with the receiver operator characteristics (ROC) curve and calibration plots. The clinical net benefit of the nomogram was assessed with decision curve analysis. Clinically significant PCa was defined as ISUP grade group > 1. RESULTS: After accounting for inclusion criteria, 1377 patients were analysed. 816/1377 (59%) had cancer at final pathology (574/816, 70%, clinically significant PCa). Multivariable analysis showed age, prostate volume, DRE and post-voided residual volume as independent predictors of any PCa. Discrimination of the nomogram for cancer was 0.70 on ROC analysis. Calibration of the nomogram was excellent (p = 0.94) and the nomogram presented a net benefit in the 40-80% range of probabilities. Multivariable analysis for predictors of clinically significant PCa found age, PSA, prostate volume and DRE as independent variables. Discrimination of the nomogram was 0.73. Calibration was poor (p = 0.001) and the nomogram presented a net benefit in the 25-75% range of probabilities. CONCLUSION: We confirmed that the Cormio nomogram can be used to predict the risk of PCa in patients at increased risk. Implementation of the nomogram in clinical practice will better define its role in the patient's counselling before prostate biopsy.
Authors: Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey Journal: Am J Surg Pathol Date: 2016-02 Impact factor: 6.394
Authors: Leonard P Bokhorst; Xiaoye Zhu; Meelan Bul; Chris H Bangma; Fritz H Schröder; Monique J Roobol Journal: BJU Int Date: 2012-10-08 Impact factor: 5.588
Authors: H Serag; S Banerjee; K Saeb-Parsy; S Irving; K Wright; S Stearn; A Doble; V J Gnanapragasam Journal: Br J Cancer Date: 2012-01-12 Impact factor: 7.640
Authors: Richard J Bryant; Daniel D Sjoberg; Andrew J Vickers; Mary C Robinson; Rajeev Kumar; Luke Marsden; Michael Davis; Peter T Scardino; Jenny Donovan; David E Neal; Hans Lilja; Freddie C Hamdy Journal: J Natl Cancer Inst Date: 2015-04-11 Impact factor: 13.506
Authors: Luigi Cormio; Luca Cindolo; Francesco Troiano; Michele Marchioni; Giuseppe Di Fino; Vito Mancini; Ugo Falagario; Oscar Selvaggio; Francesca Sanguedolce; Francesca Fortunato; Luigi Schips; Giuseppe Carrieri Journal: Front Oncol Date: 2018-10-16 Impact factor: 6.244
Authors: Ugo Giovanni Falagario; Giovanni Silecchia; Salvatore Mariano Bruno; Michele Di Nauta; Mario Auciello; Francesca Sanguedolce; Paola Milillo; Luca Macarini; Oscar Selvaggio; Giuseppe Carrieri; Luigi Cormio Journal: Front Oncol Date: 2021-01-08 Impact factor: 6.244
Authors: Cosimo De Nunzio; Jamil Ghahhari; Riccardo Lombardo; Giorgio Ivan Russo; Ana Albano; Antonio Franco; Valeria Baldassarri; Antonio Nacchia; Juan Lopez; Pilar Luque; Maria Jose Ribal; Antonio Alcaraz; Andrea Tubaro Journal: World J Urol Date: 2021-06-26 Impact factor: 4.226